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Abstract
Background: Ellagic acid (EA), a dietary polyphenolic compound, has been demonstrated to exert anti-angiogenic effect but
the detailed mechanism is not yet fully understood. The aim of this study was to investigate whether the zinc chelating
activity of EA contributed to its anti-angiogenic effect.
Methods and Principal Findings: The matrix metalloproteinases-2 (MMP-2) activity, a zinc-required reaction, was directly
inhibited by EA as examined by gelatin zymography, which was reversed dose-dependently by adding zinc chloride. In
addition, EA was demonstrated to inhibit the secretion of MMP-2 from human umbilical vein endothelial cells (HUVECs) as
analyzed by Western blot method, which was also reversed by the addition of zinc chloride. Reversion-inducing cysteine-
rich protein with Kazal motifs (RECK), known to down-regulate the MMP-2 activity, was induced by EA at both the mRNA
and protein levels which was correlated well with the inhibition of MMP-2 activity. Interestingly, zinc chloride could also
abolish the increase of EA-induced RECK expression. The anti-angiogenic effect of EA was further confirmed to inhibit
matrix-induced tube formation of endothelial cells. The migration of endothelial cells as analyzed by transwell filter assay
was suppressed markedly by EA dose-dependently as well. Zinc chloride could reverse these two effects of EA also in a
dose-dependent manner. Since magnesium chloride or calcium chloride could not reverse the inhibitory effect of EA, zinc
was found to be involved in tube formation and migration of vascular endothelial cells.
Conclusions/Significance: Together these results demonstrated that the zinc chelation of EA is involved in its anti-
angiogenic effects by inhibiting MMP-2 activity, tube formation and cell migration of vascular endothelial cells. The role of
zinc was confirmed to be important in the process of angiogenesis.
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Introduction
Ellagic acid (EA) is a dietary polyphenol known to be present
abundantly in fruits and vegetables [1–3]. The multiple effects of
EA such as antioxidant, anti-proliferative, chemopreventive, and
anti-atherogenic properties have been demonstrated in different
studies [1–9]. EA exerts its effects via activation of various
signaling pathways, including apoptosis, protection from oxidative
DNA damage or LDL-oxidation, and alteration of growth factor
expression, as well as through the expression of p53, NF-kappa B,
and peroxisome proliferator-activated receptor (PPAR) family
responsive genes [4,5,7,8,10,11]. However, only a few studies
regarding the anti-angiogenic effect of ellagic acid have been
reported. EA has been reported to act as a potent nucleoside
diphosphate kinase (NDPK-B) inhibitor and potentially might
reduce the local ATP levels and P2Y receptor-mediated
angiogenesis [12]. EA has also been demonstrated to inhibit
vascular endothelial growth factor (VEGF)-induced migration of
endothelial cells as well as their differentiation into capillary-like
tubular structures, and abolish platelet-derived growth factor
(PDGF) dependent smooth muscle cell migration [13]. The more
detailed mechanism responsible for the anti-angiogenic effect of
EA is still needed to be further explored.
Angiogenesis is known to play an important role in cancer
development for oxygen and nutrient supply [14]. Tumor cells
produce angiogenic factors including bFGF, VEGF and PDGF to
promote growth of the tumor. These angiogenic factors increase
endothelial cell permeability, migration, invasion and stabilization
of capillary tubes that are associated with the expression of matrix
metalloproteinases (MMPs), a family of zinc- and calcium-
dependent enzymes [15]. The first step in the angiogenic process
is the degradation of subendothelial basement membrane and
surrounding extracellular matrix [16]. Following matrix break-
down, endothelial cells can migrate and proliferate to form new
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e18986blood vessels. The matrix metalloproteinases (MMPs) are highly
expressed in cells that are involved in angiogenesis both in vitro [17]
and in vivo [18]. Inhibition of the early degradation of extracellular
matrixpredominantlybyMMPsisconsideredanimportantstrategy
for anti-angiogenesis. MMP-2 and MMP-9 have been considered as
enzymes in degradation of the stroma and extracellular basement
proteins to allow further differentiation and spread of endothelial
cells during angiogenesis. Reversion-inducing cysteine-rich protein
with Kazal motifs (RECK) protein is known to inhibit MMP-2 and
MMP-9 activities and lead to strong suppression of invasion,
metastasis, and tumor angiogenesis [19,20]. Therefore, the
induction or over expression of RECK by drug may be considered
as an anti-angiogenic or anti-cancer approach.
We previously reported that EA could inhibit in vivo
angiogenesis as determined by embryo chorioallantoic membrane
(CAM) vascular growth assays which was correlated well with the
direct inhibition of MMP-2 activity and the secretion of MMP-2
from human vascular endothelial cells [21]. EA has been shown to
acquire the ability to bind zinc ion and form metal-complex
[22,23]. In addition, zinc is known to act as a catalytic ion critical
for the enzymatic activity of MMP-2 protein. Therefore, in the
present study, we aimed to investigate whether the zinc chelating
activity of EA contributed to its anti-angiogenic effect.
Results
Zinc chloride reversed the direct inhibition of MMP-2
activity by ellagic acid
As reported in our previous study [21], EA could inhibit the
MMP-2 activity both in vivo and in vitro. Proteolytic degradation
of ECM components by MMP-2 is demonstrated critical for
angiogenesis. The inhibition of MMP-2 therefore contributes to
the anti-angiogenic effect of EA. Since EA is able to complex with
zinc ion and MMP-2 is a zinc-dependent enzyme, we first
examined the effect of EA directly on MMP-2 activity. As shown
in Fig. 1A, the direct incubation of conditioned medium
containing MMP-2 protein with ellagic acid dose-dependently
decreased the MMP-2 activity as measured by gelatin zymogra-
phy. By adding zinc chloride together with EA to condition
medium reversed MMP-2 activity inhibited by EA in a dose-
dependent manner (Fig. 1B). Similar results were obtained when
purified MMP-2 protein alone was incubated with EA directly
(Fig. 1C). We found that the MMP-2 activity was inhibited and
this inhibitory effect of EA could also be reversed by adding
ZnCl2. This result strongly suggested a direct binding between EA
and MMP-2 and the binding was Zn-dependent.
Direct binding of EA to MMP-2 protein was confirmed by
change of UV absorption
Most drugs have distinct UV or visible spectra because of the
conjugated chromophores in the molecule. When a drug interacts
with a protein the spectrum may be changed because of alterations
in the electronic configuration which can be used to analyze the
drug-protein interaction. As shown in figure 2A, the maximum
UV absorption for 10 mM EA was determined to be
0.88660.0684 at 280 nm. The OD280 for MMP-2 was as low as
0.03160.0015. In Fig. 2B, the absorption of EA ranged from 0.5–
10 uM at OD280 was from 0.064060079 to 0.86360.0718,
respectively. However, in the presence of MMP-2, the absorption
of EA was increased dramatically to 1.32860.0247 when EA was
10 mM. Since the OD280 for MMP-2 protein was extremely low,,
the increased UV absorption was simply due to the change of EA
configuration after binding to MMP-2 protein.
Zinc chloride reversed the inhibition of MMP-2 activity by
ellagic acid in human endothelial cells
To further study whether the effect of EA on MMP-2 activity
may also go through a cellular mechanism in HUVECs, we
examined the MMP-2 activity in HUVECs with EA treatment for
24 hours. Results revealed that the MMP-2 activity in the
conditioned medium collected from EA-treated cells for 24 hours
was dose-dependently inhibited (Fig. 3A). By adding ZnCl2,a t
concentrations ranging from 0.1 to 100 mM, the MMP-2 activity
could be dose-dependently restored (Fig. 3B). MTT assay was
performed and the results indicated that higher concentration of
EA could cause the decrease of cell number due to the inhibition
of cell proliferation, but not cell death. Since the the percentage of
cell number compared to control after EA treatment was found to
be 9866%, 9865%, 9262%, 8262% and 7660% for EA at 1,
2.5, 5, 7.5 and 10 mM, respectively, we decided to use 5 mM for
the experiments. We also performed the experiment by treating
vascular endothelial cells first with EA alone. The media were then
replaced at 1, 3, 6 and 12 hours later by fresh media containing
ZnCl2 and conditioned media were collected at 24 hours for
zymography analysis. The result shown in Fig. 3C demonstrated
that the addition of ZnCl2 even at 12 hours after the entrance of
EA into cytoplasm could partially reverse the inhibitory effect of
EA, indicating a Zn-dependent intercellular pathway is also
involved in the regulation of MMP-2 activity in HUVECs.
Zinc chloride reversed the inhibition of MMP-2 secretion
by ellagic acid
TheprocessofMMP-2secretiontotheextracellularenvironment
where it actually functions could be another critical mechanism for
the regulation of angiogenesis. In our previous study [21], we
demonstrated that the protein levels of MMP-2 in conditioned
medium after EA treatment were dose-dependently decreased and
the protein levels of MMP-2 in the cytosol were conversely
increased after EA treatment in a dose-dependent manner. The
accumulation of MMP-2 protein in the cytosol and the decrease of
MMP-2 protein in conditioned medium indicated that a cellular
mechanism was involved in the inhibited secretory pathway of
MMP-2 by EA. We further investigated whether the presence of
ZnCl2 could affect this EA effect. As shown in Fig. 4, the decreased
MMP-2 level in conditioned medium and the increased MMP-2
level in cytosol of EA-treated HUVECs were gradually reversed by
co-incubation with ZnCl2.Z n C l 2 at 10 mM totally abolished the
inhibitory effect of EA on the secretion of MMP-2 in HUVECs.
Ellagic acid enhanced the RECK expression suppressed
by zinc chloride
RECK is a novel plasma–membrane anchored protein that
regulates MMPs activity. RECK inhibits both catalytic and
processing steps of proMMP-2 activity [20] and is associated with
inhibition of MMP-2, MMP-9 and MMP-14 secretion [24]. Our
data showed that both of the mRNA and protein level of RECK
were enhanced by EA dose dependently (Fig. 5, A and B). More
interestingly, co-incubation with ZnCl2 abolished the effect of EA
on up-regulating the expression of RECK in HUVECs both at the
mRNA and protein levels (Fig. 6, A and B).
Zinc chelation is involved in the inhibitory effect of
ellagic acid on matrix-induced tube formation of human
endothelial cells
As reported by Labrecque et al. [13], we also demonstrated that
that EA ranged from 1–10 mM inhibited the matrix-induced tube
formation of HUVECs in a dose-dependent manner (data not
Ellagic Acid Inhibits Angiogenesis
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5 mM EA in the presence and absence of 100 mM ZnCl2 and the
tube formation of these cells was compared with control cells. Our
result showed that ZnCl2 completely reversed the inhibitory effect
of EA on matrix-induced tube formation (Fig. 7, A and B). In
Fig. 7C, we treated cells with ZnCl2 alone and result ruled out the
possibility that ZnCl2 itself could increase the tube formation of
HUVECs. In order to further verify the role of zinc in matrix-
induced tube formation, HUVECs were treated 5 mM EA in the
presence of 100 mM Zn(C2H3O2)2, CaCl2 or MgCl2. We found
that only 100 mM Zn(C2H3O2)2 reversed the tube formation
inhibited by EA. Neither CaCl2 nor MgCl2 could reverse the
inhibitory effect of EA (Fig. 7D). These observations clarified that
zinc chelation was responsible for the inhibitory effect of EA on the
matrix-induced tube formation of HUVECs.
Zinc chelation is involved in the inhibitory effect of
ellagic acid on migration of human endothelial cells
In our previous study, we also demonstrated that EA ranged
from 1–10 mM dose-dependently inhibited the migration of
Figure 1. Zinc chloride reversed the direct inhibition of MMP-2 activity by ellagic acid. A. EA directly inhibited the MMP-2 activity in cell-
free conditioned medium dose-dependently. B. Co-incubation with ZnCl2 reversed the direct inhibition of MMP-2 activity in cell-free conditioned
medium by EA. Conditioned medium containing the MMP-2 activity was taken from cultures of HUVECs. C. The activity of purified MMP-2 in the
presence of EA was inhibited which could also be reversed by ZnCl2 dose-dependently.
doi:10.1371/journal.pone.0018986.g001
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presence and absence of 100 mM ZnCl2 and the migration of these
cells was compared with control cells. Our result showed that
ZnCl2 completely reversed the inhibitory effect of EA on cell
migration (Fig. 8, A and B). In order to further verify the role of
zinc in cell migration, HUVECs were treated 5 mM EA in the
presence of 100 mM Zn(C2H3O2)2, CaCl2 or MgCl2. We found
that only 100 mM Zn(C2H3O2)2 reversed the migration inhibited
by EA. Neither CaCl2 nor MgCl2 could reverse the inhibitory
effect of EA (Fig. 8C). These observations clarified that zinc
chelation was involved in the inhibitory effect of EA on the
migration of HUVECs.
Discussion
As reported in our previous study, EA is the active compound in
P. urinaria that exhibits anti-angiogenic activity and inhibits the
secretion of MMP-2 protein from HUVECs [21]. MMP-2, like
other MMPs, is a zinc-dependent endopeptidase involved in the
degradation of the ECM and plays a role in normal tissue
remodeling events such as embryonic development, angiogenesis,
tumor migration and wound healing. As zinc is essential for
endopeptidase proteolytic capacity to degrade the ECM, com-
pounds with zinc-chelating groups, such as thiol or hydroxamate
[25], are often used to inhibit the MMP activity. These inhibitors
can chelate zinc ion by imposing a distinct bidentate interaction
with zinc and form a stable conformation [26]. Matrix
metalloproteinase inhibitors (MMPIs) such as batamastat and
marimastat are synthetic, low-molecular weight compound with a
collagen-mimicking hydroxamate structure to exert chelation of
the zinc ion in the active site of the MMPs and act as competitive
MMP-inhibitors and exert anti-angiogenesis effect [27]. Since the
direct co-incubation of purified MMP-2 protein with EA inhibited
the MMP-2 activity and addition of ZnCl2 reversed the effect of
EA, the anti-angiogenic effect of EA is at least in part mediated
similarly as that of MMPIs by chelating the zinc and directly
inhibiting MMP-2 activity. The evidence to show the direct
binding of EA to Zn has been suggested by previous reports
regarding the anchor of EA to the Zn-coordinated water molecule
by its phenol group [22] and the formation of EA-Zn complex
[23]. The present study demonstrated the direct binding of EA to
MMP-2 protein by measuring the change of UV absorption,
confirming the zinc-chelating effect of EA plays an important role
in inhibiting the MMP-2 activity directly.
In addition to the direct inhibitory effect on MMP-2 activity
mediated by zinc chelation, the treatment of endothelial cells with
Figure 2. Ellagic acid directly bound to MMP-2 protein as demonstrated by the change of UV absorption. A. The spectral absorptions of
10 mM EA and 0.2 ng MMP-2 were measured at 260, 280, 405, 450 and 490 nm. B. The spectral absorptions at 280 nm for EA ranged from 0.5–10 mM
in the absence or presence of MMP-2 protein were measured.
doi:10.1371/journal.pone.0018986.g002
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therefore further reduced extracellular MMP-2 activity [21].
Interestingly, the inhibition of MMP-2 secretion by EA was also
reversible in the presence of ZnCl2, indicating a cellular
mechanism involved which was also zinc-dependent. The cellular
secretory process allows rapid mobilization and utilization of
MMP-2 enzymes in the early phase of angiogenesis [28]. Among
the regulators reported to be involved in the secretion of MMP-2,
RECK was recently found to play an important role in this
process. RECK protein was initially discovered by its ability to
induce reversion in ras-activated fibroblasts. The key action of
RECK is to inhibit MMPs such as MMP-2, MMP-9 and MT-
MMP-1. The suppression of RECK expression has been found in
the studies of a number of human tumors including colorectal,
breast, pancreas, gastric, hepatocellular, prostate, and non-small
cell lung carcinoma [29]. Therefore, the up-regulation of the
RECK expression is considered potentially as a therapeutic
approach to limit cancer angiogenesis and metastasis by
suppressing vessel branching via MMPs inhibition. Our results
demonstrated that the EA-induced RECK expression was
associated with the decrease of MMP-2 secretion, enzymatic
activity and inhibition of angiogenesis. We also showed, for the
Figure 3. Zinc chloride reversed the inhibition of MMP-2 activity by ellagic acid in human endothelial cells. A. EA dose-dependently
inhibited the MMP-2 activity of HUVECs. B. Co-incubation of 5 mM EA with ZnCl2 ranged from 0–100 mM for 24 hours reversed the inhibition of MMP-
2 activity of HUVECs by EA. C. HUVECs were treated first with 5 mM EA alone and the culture media were replaced at 1, 3, 6 and 12 hours later by fresh
culture media containing 100 mM ZnCl2. Conditioned media were collected 24 hours later and used for the gelatin zymography analysis.
doi:10.1371/journal.pone.0018986.g003
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transcriptional and translational levels was mediated by withhold-
ing of a cellular zinc-dependent pathway, further suggesting the
important role of zinc in the process of angiogenesis.
There are eleven zinc-dependent histone deacetylases (HDAC)
in humans which modify histones and many non-histone protein
substrates. Some substrates of these enzymes include proteins that
are known to have a role in cancer growth and angiogenesis [30].
Many of the known HDAC inhibitors (HDACIs) that are in
clinical trials also possess a hydroxamate group to chelate the zinc
and inhibit HDAC activity [31,32]. The inhibition of HDAC
causes hyperacetylation of histones leading to differentiation,
growth arrest and apoptosis of malignant cells, representing a new
strategy in cancer therapy. RECK is frequently silenced in
aggressive tumor cells by the HADC/SP1 binding in the RECK
promoter [33]. HDACIs such as trichostatin A and butyric acid
exert anti-angiogenic and anti-metastatic effects both in vitro and
in vivo known to be mediated by the up-regulation of RECK that
blocks MMP-2 activity [34]. Since the function of HDAC relies on
the presence of zinc, the chelation of zinc by EA functions also as a
HDACI which abolishes the activity of HDAC and therefore up-
regulates the RECK and down-regulates MMP-2 activity. The
addition of zinc reverses the effect of EA so that MMP-2 activity
remains active when RECK expression is low.
As a potential anti-cancer drug, the zinc-chelatuing effect of
ellagic acid may also play a role on preventing the early tumor
promotion. EA has been found to exhibit antioxidative activity.
Besides scavenging free radicals, antioxidants may inhibit signaling
Figure 4. Zinc chloride reversed the inhibition of MMP-2 secretion by ellagic acid. Cells treated without or with EA in the presence or
absence of ZnCl2 for 24 hours were processed for Western blot method to analyze the protein levels of MMP-2 in conditioned media and in cytosol.
doi:10.1371/journal.pone.0018986.g004
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tumor promotion [35]. Oxidant tumor promoters activate PKC by
reacting with zinc-thiolates present within the regulatory domain.
EA can inactivate PKC by chelating the zinc and oxidizing the
vicinal thiols present within the catalytic domain and block the
signal transduction induced by tumor promoters. The redox-
mediated inactivation of PKC may, at least in part, be responsible
for the antioxidant-induced inhibition of tumor promotion and cell
growth. Oxidative stress also represents an important stimulus that
widely contributes to tumor angiogenesis mediating the angiogenic
switch that can be produced by cancer cells and thus contribute to
neoplastic transformation and angiogenesis [36]. We believe that
the antioxidative activity of EA may also help to reduce the
oxidative stress, particularly those produced from zinc-induced
oxidation in the cells which deserved further investigation in the
future.
In summary, we found that EA can inhibit the activity and the
secretion of MMP-2 in human vascular endothelial cells likely
mediated by the induction of RECK expression. EA also inhibits
the tube formation and migration of human vascular endothelial
cells in a dose-dependent manner. These anti-angiogenic effects
caused by EA can all be reversed by the addition of zinc,
demonstrating the zinc-chelating activity of ellagic acid and also
elucidating the important role of zinc in the process of
angiogenesis. Compared with either MMPIs or HDACIs that
bind mainly to active zinc-containing domain of specific protein
targets, the zinc-chelating effect of EA is much more wide-ranging
and therefore may be considered as a more effective anti-
angiogenic or anti-cancer drug with greater potential. It is known
that EA exhibits multiple effects in a variety of tissues and cells,
which may simultaneously trigger various molecular mechanisms
that help to increase the effectiveness when it is used to inhibit
cancer development or tumor angiogenesis.
Materials and Methods
Cell culture
Human endothelial cells were isolated from the vein of human
umbilical cords and grown in EGM provided by Clonetics (MD,
U.S.A.). Cells were maintained in a humidified atmosphere with
5% CO2/95% air at 37uC. Human umbilical vein endothelial cells
(HUVECs) were passaged 3–5 times prior to use in experiments.
To examine the effect of EA on cell function, cells at 80–90%
confluency were treated with 0–10 mM EA for 24 hours.
MTT assay
Cells with or without ellagic acid treatment were washed once
with PBS, followed by adding 1 ml DMEM containing 0.05 mg/
ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). After incubation at 37uC for 1 h, the media were
removed and the formazan crystals in the cells were solubilized
in 1 ml DMSO for OD (optical density) reading at 570 nm using a
spectrophotometer.
Zymography analysis
Conditioned medium collected from cultures of HUVECs or
purified MMP-2 protein were directly processed for analysis on
MMP-2 activity. The effect of EA was tested by incubating EA
with conditioned medium or purified MMP-2 protein for
10 minutes at room temperature and processed for zymographic
analysis. Samples were loaded onto 10% SDS-PAGE gels in which
1% gelatin (Amersham Life Science,Cleveland,OHIO,USA) was
incorporated. After migration, gels were incubated with 2.5%
Triton-X 100 twice for 30 min at room temperature, washed for
5 min in TNCA (50 mM Tris pH 7.5, 200 mM NaCl, 5 mM
CaCl2) and further incubated for 16 hrs in TNCA in a shaking
bath at 37uC. Gels were stained for 1 hr in coomassie blue (0.1%
coomassie brillant blue R-250, 50% methanol, 10% acetic acid)
and destained in 5% methanol/9% acetic acid until proper
contrast was achieved. White bands on blue background indicated
zones of digestion corresponding to the presence of different
MMPs.
RNA isolation and RT-PCR
Total cellular RNA was isolated by lysis of cells in a
guanidinium isothiocyanate buffer, followed by single step
phenol-chloroform-isoamyl alcohol extraction procedure modified
from that previously described [37]. Briefly, EA treated with or
without ZnCl2 cells were harvested and lysed in 4 M guanidinium
isothiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sodium
sarkosine and 0.1 M ß-mercaptoethanol. Sequentially, 1/10
volume of 2 M sodium acetate (pH 4.0), one volume of phenol
and 1/5 volume of chloroform-isoamyl alcohol (49:1, v:v) were
added to the homogenate. After vigorous vortexing for 30 sec, the
solution was centrifuged at 10,0006 g for 15 min at 4uC. After
removal of the aqueous phase, RNA was precipitated by the
addition of 0.5 mL isopropanol. One mg of total RNA was reverse-
Figure 5. Ellagic acid upregulated the RECK expression. The
effect of EA treatment for 24 hours on the expression of RECK in
HUVECs was analyzed at the A. mRNA and B. protein levels as measured
by RT-PCR and Western blot analysis.
doi:10.1371/journal.pone.0018986.g005
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transcriptase in 20 mL of reaction buffer containing 0.25 mgo f
random primers and 0.8 mM dNTPs at 42uC for 60 min. Two mL
of cDNA was used as template for the PCR reaction. PCR was
performed in buffer containing 10 mM Tris, pH 8.3, 50 mM
KCL, 1.5 mM MgCl2, 0.2 mM dNTPs, 1 mM of each primer and
5 units Taq DNA polymerase for 30 cycles of denaturation at
94uC for one min, annealing at 55uC for one min and extension at
72uC for two min. The resulting PCR product was analyzed by
EtBr stained 1.5% agarose gel electrophoresis. Sequences for the
specific primers used in the PCR are MMP-2 forward primer (59-
GTTTCCATTCCGCTTCCAGG-39) and reverse primer (59-
TGCCCTTGATGTCATCCTGG-39); RECK forward primer
(59-AAGTCTTGTATTGTTGGAGGAA-39) and reverse primer
(59-ACTGATGGTCTTGGAGGC-39); GAPDH forward primer
(59-TTCATTGACCTCAACTACAT-39) and reverse primer (59-
GAGGGGCCATCCACAGTCTT-39).
Western blotting
Protein concentrations were determined by the Bradford
method (Bio-Rad, CA). HUVECs were harvested for protein
analysis. Samples with equal amount of proteins were subjected to
10% sodium dodecyl sulfate (SDS) polyacrylamide gel electropho-
resis (PAGE) and transferred onto a polyvinylidene difluoride
(PVDF) (Millipore, Bedford, MA, USA) membrane. The mem-
brane was incubated at room temperature in blocking solution
(1%BSA, 1%goat serum in PBS) for 1 hour, followed by a 2 hour
incubation in blocking solution containing an appropriate dilution
Figure 6. Zinc chloride suppressed the RECK expression enhanced by ellagic acid. The effect of ZnCl2 co-incubation with EA on the
expression of RECK in HUVECs was analyzed at the A. mRNA and B. protein levels as measured by RT-PCR and Western blot analysis.
doi:10.1371/journal.pone.0018986.g006
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Marks, Fremonk, CA, USA) and anti-RECK. After washing, the
membrane was incubated in PBS containing goat anti-mouse IgG
conjugated with horseradish peroxidase (Sigma, St. Louis, MO,
USA) for 1 hour. The membrane was washed and the positive
signals were developed with chemiluminescence reagent (Amer-
shan Pharmacia Biotech, Little Chalfont Buckinghamshire,
England). Membrane was exposed to Fuji medical X-ray film
(Fuji Ltd,Tokyo, Japan) for 30 minutes.
ECM gel-induced capillary tube formation
The extra cellular matrix (ECM) gel-induced capillary tube
formation assay was used as an in vitro measurement of angiogenesis.
Briefly, 24-well culture plate was coated with 75 ml/well ECM gel
(11.34 mg/ml) prepared from Engelbreth Holm-Swarm mouse
sarcoma (Sigma) and allowed to stand for 30 minutes at 37uCt o
form a gel layer. After gel formation, 7|10
4 HUVECs in 0.5 ml of
growth medium were seeded to each well. The plate was incubated
at 37uC in a humidified atmosphere with 5% CO2/95% air for
4 hours and the formation of capillary tubes were photographed
with the use of an inverted microscope.
Transwell filter migration assay
Transwell filters (Costar, Cambridge, MA) with 8.0 mm pores
were used for migration assay. HUVECs were seeded at a density of
1.2610
5 cells per filter. To initiate the chemotaxis assay, cells in
Figure 7. Zinc reversed the matrix-induced tube formation of HUVECs inhibited by EA. A. and B. Cells were treated with 5 mM ellagic acid
in the presence of ZnCl2 ranged from 0–100 mM for 24 hours. C. Cells were treated with or without 100 mM ZnCl2 for 24 hours and processed for tube
formation analysis. D. Cells were treated with 5 mM EA in the presence of 100 mM Zn(C2H3O2)2, Ca Cl2 or MgCl2 for 24 hours and processed for tube
formation analysis. The number of completely formed tubes in each group was determined and compared. Values are mean (n=3) 6 SEM. An
asterisk demonstrated the significant difference (p,0.05) between none-treated and EA-treated groups.
doi:10.1371/journal.pone.0018986.g007
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the lower chamber was filled with 600 ml DMEM and 10% FCS as
an inducer ofcell migration. Cells wereallowedto migratefor2 h at
37uC in an atmosphereof 95%air/5%CO2. Cells on the filterwere
first stained with Liu’s stain and cells that remained on the upper
surfaceof the filterwere removed using a cottonswab. Thecells that
migrated onto the lower surface of the filter were examined by
microscope after mounting on a slide. Total six random high-power
microscopic fields (HPF) (1006) per filter were photographed and
the numbers of cells were directly counted.
Statistical analysis
All statistical analyses were performed using SigmaStat
statistical software (version 2.0, Jandel Scientific, CA, U.S.A).
Results were represented as means 6 STD. Analysis of variance
(ANOVA) was carried out when multiple comparisons were
evaluated. Values were considered to be significant at p less than
0.05.
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Figure 8. Zinc reversed the migration of HUVECs inhibited by EA. A. and B. Cells were treated with 5 mM EA in the presence of ZnCl2 ranged
from 0–100 mM for 24 hours. C. Cells were treated with 5 mM EA in the presence of 100 mM Zn(C2H3O2)2, Ca Cl2 or MgCl2 for 24 hours and processed
for migration assay. Values are mean (n=3) 6 SEM. An asterisk demonstrated the significant difference (p,0.05) between none-treated and EA-
treated groups.
doi:10.1371/journal.pone.0018986.g008
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